Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark T Esser

Showing results (11-20 of 99) with videos related to

Pageof 10
Sort By:
Human Vaccines & Immunotherapeutics|March 12, 2019
Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adultsAdriana Weinberg, Stacie L Lambert, Jennifer Canniff, et al.
Vaccine|January 18, 2003
Memory T cells and vaccinesMark T Esser, Rocio D Marchese, Lisa S Kierstead, et al.
Clinical and Diagnostic Laboratory Immunology|January 11, 2003
Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assayDavid Opalka, Charles E Lachman, Stefani A MacMullen, et al.
Clinical and Vaccine Immunology : CVI|March 19, 2010
Multiplexed serologic assay for nine anogenital human papillomavirus typesDavid Opalka, Katie Matys, Paul Bojczuk, et al.
Antimicrobial Agents and Chemotherapy|December 14, 2016
Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy AdultsM Pamela Griffin, Anis A Khan, Mark T Esser, et al.
The Pediatric Infectious Disease Journal|January 27, 2018
Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm InfantsJoseph B Domachowske, Anis A Khan, Mark T Esser, et al.
Antimicrobial Agents and Chemotherapy|March 27, 2024
Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19Lindsay E Clegg, Oleg Stepanov, Henning Schmidt, et al.
Clinical and Vaccine Immunology : CVI|February 28, 2014
Enzyme-linked immunospot assay for detection of human respiratory syncytial virus f protein-specific gamma interferon-producing T cellsKathryn Patton, Shahin Aslam, Jim Lin, et al.
The Journal of Infectious Diseases|October 14, 2017
An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older AdultsJudith Falloon, Jing Yu, Mark T Esser, et al.
Vaccine|July 25, 2015
Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaquesKathryn Patton, Shahin Aslam, Cindy Shambaugh, et al.
Pageof 10

Showing results (11-20 of 99) with videos related to

Sort By:
Pageof 10
Human Vaccines & Immunotherapeutics|March 12, 2019
Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adultsAdriana Weinberg, Stacie L Lambert, Jennifer Canniff, et al.
Vaccine|January 18, 2003
Memory T cells and vaccinesMark T Esser, Rocio D Marchese, Lisa S Kierstead, et al.
Clinical and Diagnostic Laboratory Immunology|January 11, 2003
Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assayDavid Opalka, Charles E Lachman, Stefani A MacMullen, et al.
Clinical and Vaccine Immunology : CVI|March 19, 2010
Multiplexed serologic assay for nine anogenital human papillomavirus typesDavid Opalka, Katie Matys, Paul Bojczuk, et al.
Antimicrobial Agents and Chemotherapy|December 14, 2016
Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy AdultsM Pamela Griffin, Anis A Khan, Mark T Esser, et al.
The Pediatric Infectious Disease Journal|January 27, 2018
Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm InfantsJoseph B Domachowske, Anis A Khan, Mark T Esser, et al.
Antimicrobial Agents and Chemotherapy|March 27, 2024
Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19Lindsay E Clegg, Oleg Stepanov, Henning Schmidt, et al.
Clinical and Vaccine Immunology : CVI|February 28, 2014
Enzyme-linked immunospot assay for detection of human respiratory syncytial virus f protein-specific gamma interferon-producing T cellsKathryn Patton, Shahin Aslam, Jim Lin, et al.
The Journal of Infectious Diseases|October 14, 2017
An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older AdultsJudith Falloon, Jing Yu, Mark T Esser, et al.
Vaccine|July 25, 2015
Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaquesKathryn Patton, Shahin Aslam, Cindy Shambaugh, et al.
Pageof 10